Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q4 2020 | 2021-03-17 | Future report Set alerts | |
Q3 2020 | 2020-11-03 | 0.00 | 0.00 |
Q2 2020 | 2020-08-04 | -0.17 | -0.17 |
Q1 2020 | 2020-06-24 | 0.00 | -0.28 |
Q4 2019 | 2020-06-24 | 0.00 | -0.26 |
Q3 2019 | 2020-06-24 | 0.00 | -0.19 |
Q2 2019 | 2020-06-24 | 0.00 | -0.22 |
Q1 2019 | 2020-05-12 | 0.00 | -0.30 |
Q4 2018 | 2019-03-26 | -0.18 | -0.18 |
Q3 2018 | 2018-11-01 | -0.22 | -0.22 |
2016-06-13 | Reiterated Rating | FBR & Co. | Buy | |
2016-06-13 | Reiterated Rating | FBR & Co | Buy | |
2016-06-03 | Reiterated Rating | Robert W. Baird | Outperform | $7.00 |
2016-05-10 | Reiterated Rating | FBR & Co. | Buy | |
2016-05-05 | Initiated Coverage | Cowen and Company | Outperform | |
2016-04-27 | Reiterated Rating | Cowen and Company | Outperform | |
2016-03-01 | Initiated Coverage | SunTrust | Buy | $3.00 |
2016-03-01 | Initiated Coverage | SunTrust Banks Inc. | Buy | $3.00 |
2016-02-29 | Reiterated Rating | Roth Capital | Buy | $5.00 |
2015-11-09 | Lower Price Target | Roth Capital | Buy | $6.00 to $5.00 |
2015-10-19 | Reiterated Rating | Robert W. Baird | Buy | $7.00 |
2015-10-19 | Reiterated Rating | Roth Capital | Buy | $5.00 |
2015-08-11 | Initiated Coverage | FBR & Co. | Outperform | $6.00 |
2015-08-10 | Lower Price Target | Roth Capital | Buy | $6.00 to $5.00 |
2015-07-25 | Reiterated Rating | Roth Capital | Buy | |
2015-07-06 | Reiterated Rating | Oppenheimer | Outperform | |
2015-07-06 | Reiterated Rating | Oppenheimer Holdings Inc. | Outperform | |
2015-06-02 | Set Price Target | Roth Capital | Buy | $6.00 |
2015-06-01 | Boost Price Target | Robert W. Baird | Outperform | $5.00 to $7.00 |
2015-05-16 | Reiterated Rating | Stifel Nicolaus | Hold | |
2015-04-20 | Set Price Target | Robert W. Baird | Buy | $5.00 |
2015-01-22 | Boost Price Target | Oppenheimer | Outperform | $3.00 to $5.00 |
2015-01-21 | Lower Price Target | Roth Capital | Buy | $10.00 to $6.00 |
2014-10-16 | Reiterated Rating | Roth Capital | Positive | |
2014-05-09 | Lower Price Target | Oppenheimer | Outperform | $4.50 to $3.00 |
2014-03-24 | Lower Price Target | Roth Capital | $10.00 to $9.00 | |
2013-12-05 | Initiated Coverage | Wedbush | Outperform | $6.00 |
2013-11-21 | Lower Price Target | Mackie | Speculative Buy | C$1.80 to C$1.20 |
2013-11-07 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $8.00 to $3.00 |
2013-10-01 | Initiated Coverage | Robert W. Baird | Outperform | $7.00 |
2013-09-30 | Initiated Coverage | Chardan Capital | Buy | $6.00 |
2012-01-31 | Reiterated | Summer Street Research | Buy | $5 to $7 |
2011-10-06 | Initiated | Summer Street Research | Buy | $5 |
2011-09-22 | Initiated | MLV Capital | Buy | $8.50 |
2011-03-21 | Reiterated | Brean Murray | Buy | $4 to $5 |
2010-02-26 | Reiterated | Roth Capital | Buy | $5 to $4.50 |
2010-01-07 | Initiated | Roth Capital | Buy | $5 |
2009-11-24 | Initiated | ThinkEquity | Buy | |
2009-03-25 | Initiated | Merriman Curhan Ford | Buy |
2016-06-13 | Reiterated Rating | FBR & Co. | Buy | |
2016-06-13 | Reiterated Rating | FBR & Co | Buy | |
2016-06-03 | Reiterated Rating | Robert W. Baird | Outperform | $7.00 |
2016-05-10 | Reiterated Rating | FBR & Co. | Buy | |
2016-05-05 | Initiated Coverage | Cowen and Company | Outperform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CRIS 45 funds of 2197 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Fund Advisors | 5.55M |
Sio Capital Management, LLC | 4.95M |
BVF INC/IL | 3.65M |
BlackRock Institutional Trust Company, N.A. | 3.15M |
RENAISSANCE TECHNOLOGIES LLC | 1.54M |
ORBIMED ADVISORS LLC | 1.24M |
Vanguard Group, Inc | 1.20M |
SABBY MANAGEMENT, LLC | 1.18M |
J. Goldman & Co LP | 0.51M |
BlackRock Investment Management, LLC | 0.45M |
BlackRock Inc. | 0.43M |
GSA CAPITAL PARTNERS LLP | 0.30M |
GEODE CAPITAL MANAGEMENT, LLC | 0.26M |
BRIDGEWAY CAPITAL MANAGEMENT INC | 0.25M |
PURA VIDA INVESTMENTS, LLC | 0.20M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
Fattaey Ali Ph.D. President & COO | 0.37% (322140) | CRIS / |
Rubin Marc | 0.28% (236596) | CRIS / GALT / TTNP / |
GREENACRE MARTYN D | 0.26% (222945) | CRIS / NBS / |
KAITIN KENNETH I | 0.25% (214607) | CRIS / |
Dentzer James E Chief Financial Officer | 0.25% (212011) | CRIS / DRNA / |
PASSERI DANIEL R CEO and Director | 0.25% (211798) | CRIS / |
Martell Robert | 0.22% (185000) | CRIS / |
Kunkel Lori Anne | 0.22% (185000) | CRIS / LOXO / |
Tuck David Chief Medical Officer | 0.20% (169424) | CRIS / |
TOBIN JAMES R | 0.17% (144921) | CRIS / GMED / OXFD / |
GRAY MICHAEL COO and CFO | 0.12% (107304) | CRIS / |
MCNAB JAMES R | 0.06% (50000) | CRIS / TTNP / |
Pienta Kenneth | 0.03% (30000) | CRIS / |
NOEL MARK Vice-President | 0.03% (27540) | CRIS / |
BAYH SUSAN B | 0.03% (25000) | CRIS / DNDN / DYAX / EMMS / MRNA / |